FDA Approved: MONTELUKAST — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

The FDA approved a supplemental application for Montelukast from BluePoint Laboratories under an ANDA, resulting in regulatory approval of this generic product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Asthma
• Exercise-induced Bronchoconstriction

Drugs mentioned

• Montelukast (Montelukast)

Snippet

SUPPL AP for MONTELUKAST (MONTELUKAST)